Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henggeliejing in Type 2 Diabetes Mellitus with NAFLD
ChiCTR2300077333Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of henagliflozin in type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and 1 more (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Ultrasound attenuation parameter, Liver stiffness measurement and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on ChiCTR2300077333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077333.